Yayın:
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTurhal, N. S.
dc.contributor.authorBaşak Oyan
dc.contributor.authorÖzlem Sönmez
dc.contributor.authorArda Ulaş Mutlu
dc.contributor.authorMuhammed Mustafa Atçı
dc.contributor.authorAbdullah Sakin
dc.contributor.authorİrem Öner
dc.contributor.authorHavva Yeşil Çınkır
dc.contributor.authorMelek Karakurt Eryılmaz
dc.contributor.authorDilek Çağlayan
dc.contributor.authorOnur Yazdan Balçık
dc.contributor.authorNail Paksoy
dc.contributor.authorSenem Karabulut
dc.contributor.authorDerya Kıvrak Salim
dc.contributor.authorCemil Bilir
dc.contributor.authorMiraç Özen
dc.contributor.authorMelike Özçelik
dc.contributor.authorAli Arıcan
dc.contributor.authorBaran Akagündüz
dc.contributor.authorAli̇ İnal
dc.contributor.authorDinçer Aydın
dc.contributor.authorLeyla Özer
dc.contributor.authorAhmet Gülmez
dc.contributor.authorN. S. Turhal
dc.contributor.authorSeli̇n Aktürk Esen
dc.contributor.authorEfnan Algın
dc.contributor.authorSinem Akbaş
dc.contributor.authorYakup İriağaç
dc.contributor.authorTeoman Şakalar
dc.contributor.authorÇağlar Ünal
dc.contributor.authorÖzlem Er
dc.contributor.authorŞaban Seçmeler
dc.contributor.authorMustafa Bozkurt
dc.contributor.orcid0000-0002-1686-1628
dc.contributor.orcid0000-0002-6656-9000
dc.contributor.orcid0000-0001-7499-7155
dc.contributor.orcid0000-0002-1300-3695
dc.contributor.orcid0000-0003-2538-8569
dc.contributor.orcid0000-0001-9486-6187
dc.contributor.orcid0000-0002-7870-8741
dc.contributor.orcid0000-0003-2597-5931
dc.contributor.orcid0000-0003-4629-6815
dc.contributor.orcid0000-0002-3386-2075
dc.contributor.orcid0000-0003-4636-2595
dc.contributor.orcid0000-0003-4740-9973
dc.contributor.orcid0000-0003-4107-3460
dc.contributor.orcid0000-0002-1372-4791
dc.contributor.orcid0000-0002-1934-0190
dc.contributor.orcid0000-0003-0406-715X
dc.contributor.orcid0000-0002-6099-2000
dc.contributor.orcid0000-0002-4979-3123
dc.contributor.orcid0000-0002-0690-2529
dc.contributor.orcid0000-0002-7433-3591
dc.contributor.orcid0000-0002-1430-2662
dc.contributor.orcid0000-0002-3353-344X
dc.contributor.orcid0000-0002-1013-5676
dc.contributor.orcid0000-0002-3426-9505
dc.contributor.orcid0000-0002-8917-9267
dc.contributor.orcid0000-0001-7411-1705
dc.contributor.orcid0000-0003-2749-9414
dc.contributor.orcid0000-0003-3245-1570
dc.contributor.orcid0000-0002-9272-2400
dc.contributor.orcid0000-0001-8421-9234
dc.contributor.orcid0000-0002-4400-6696
dc.date.accessioned2025-11-13T11:41:34Z
dc.date.issued2024-01-02
dc.identifier.doi10.1186/s12885-023-11783-5
dc.identifier.endpage16
dc.identifier.issn1471-2407
dc.identifier.issue1
dc.identifier.openalexW4390499048
dc.identifier.startpage16
dc.identifier.urihttps://hdl.handle.net/11421/7649
dc.identifier.urihttps://doi.org/10.1186/s12885-023-11783-5
dc.identifier.volume24
dc.language.isoen
dc.relation.ispartofBMC Cancer
dc.rightsopenAccess
dc.subjectRegorafenib
dc.subjectMedicine
dc.subjectColorectal cancer
dc.subjectInternal medicine
dc.subjectHazard ratio
dc.subjectChemotherapy
dc.subjectOncology
dc.subjectSurgical oncology
dc.subjectPlacebo
dc.subjectFluorouracil
dc.subjectRegimen
dc.subjectBevacizumab
dc.subjectOxaliplatin
dc.subjectSurgery
dc.subjectCancer
dc.subjectConfidence interval
dc.subjectPathology
dc.subject.sdg3
dc.titleComparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5064011743

Dosyalar

Koleksiyonlar

Publications